Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 15/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 6/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.34 |
| ▸ | ICMT | O60725 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3207678 | 0.92 | CYP3A4 (0.36) | HTR1AADRA1ADRD2CYP3A4HTT | |
| SCHEMBL3202555 | 0.88 | OPRM1 (0.44) | HTR1ADRD2CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2765720 | 0.86 | MEN1 (0.42) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL2765724 | 0.82 | MEN1 (0.40) | CYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3207505 | 0.78 | MAPT (0.33) | HTR1AADRA1ACYP3A4HTTSMN1; SMN2 | |
| SCHEMBL3195997 | 0.74 | SLC6A4 (0.36) | HTTSMN1; SMN2 | |
| SCHEMBL13382449 | 0.68 | OPRM1 (0.38) | — | |
| SCHEMBL3194845 | 0.68 | OPRM1 (0.38) | — | |
| SCHEMBL3205709 | 0.67 | MAOA (0.39) | HTR1AADRA1ADRD2CXCR2 | |
| SCHEMBL3202561 | 0.66 | OPRM1 (0.40) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-7691893-B2 | Chemical compounds | GLAXO GROUP LIMITED (GB) | 2010-04-06 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | BERTANI BARBARA | 2010-02-11 | — | — | US | disclosed |
| EP-2064186-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | Glaxo Group Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| US-20080114049-A1 | CHEMICAL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| WO-2008031772-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | GLAXO GROUP LIMITED (GB) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114049-A1 | CHEMICAL COMPOUNDS | SLC6A2, HTR3C, SLC6A3 | HTR1A 12/4885ADRA1A 42/4885DRD2 30/4885 |
| US-20100035914-A1 | AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE | SLC6A2, NPY5R, SLC6A3 | HTR1A 22/4885ADRA1A 31/4885DRD2 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.